The interviewer asks the female participant whether she has ever received a human papillomavirus (HPV) vaccination. If she answers yes, the interviewer asks her age and how many shots she received. If the participant answers "yes" to question 1, the interviewer should complete the rest of the protocol. If the participant answers "no" then the protocol is deemed complete. The PhenX Working Group notes that GARDASIL® is also known as Silgard. European Medicines Agency. (September 25, 2009). Silgard European Public Assessment Report. Retrieved from http://www.emea.europa.eu/humandocs/Humans/EPAR/silgard/silgard.htm. Waknine, Yael. (October 2, 2006). International Approvals: Singulair and Gardasil/Silgard. Medscape Today. Retrieved from http://www.medscape.com/viewarticle/545374.
status
DISCOURAGED
Fully-Specified Name
component
PhenX - human papillomavirus vaccine use protocol 100801
property
-
time
Pt = Point in time: To identify measures at a point in time. This is a synonym for “spot” or “random” as applied to urine measurements.
system
^Patient
scale
-
method
PhenX
Additional Names
short name
HPV vaccine use proto; Pan; Panel; PANEL.PHENX; Panl; Pnl; Point in time; Random
Quick, Current, Complete - www.findacode.com